Yesterday, Oct. 1, 2015, 39 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $22.95 to $44,625,000.00.

Highlighted Stocks Traded by Insiders:

Cell Therapeutics (CTIC) - FREE Research Report

Nudelman Phillip M Phd, who is Director at Cell Therapeutics, sold 150,000 shares at $1.45 on Oct. 1, 2015. Following this transaction, the Director owned 342,174 shares meaning that the stake was reduced by 30.48% with the 150,000-share transaction.

Bianco James A, who is President and CEO at Cell Therapeutics, sold 600,000 shares at $1.43 on Oct. 1, 2015. Following this transaction, the President and CEO owned 3.2 million shares meaning that the stake was reduced by 15.7% with the 600,000-share transaction.

Love Richard L, who is Director at Cell Therapeutics, sold 13,660 shares at $1.45 on Oct. 1, 2015. Following this transaction, the Director owned 530,449 shares meaning that the stake was reduced by 2.51% with the 13,660-share transaction.

Singer Jack W, who is EVP, Global Medical Affairs at Cell Therapeutics, sold 100,000 shares at $1.42 on Oct. 1, 2015. Following this transaction, the EVP, Global Medical Affairs owned 1.4 million shares meaning that the stake was reduced by 6.89% with the 100,000-share transaction.

Plunkett Matthew, who is EVP, Corporate Development at Cell Therapeutics, sold 75,000 shares at $1.41 on Oct. 1, 2015. Following this transaction, the EVP, Corporate Development owned 650,084 shares meaning that the stake was reduced by 10.34% with the 75,000-share transaction.

The shares most recently traded at $3.01, up $1.60, or 53.02% since the insider transaction. Historical insider transactions for Cell Therapeutics go as follows:

  • 4-Week # shares sold: 110,869
  • 12-Week # shares sold: 160,869
  • 24-Week # shares sold: 265,869

The average volume for Cell Therapeutics has been 3.7 million shares per day over the past 30 days. Cell Therapeutics has a market cap of $440.5 million and is part of the health care sector and drugs industry. Shares are up 53.93% year-to-date as of the close of trading on Tuesday.

CTI BioPharma Corp., a biopharmaceutical company, engages in the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally.

Exclusive Offer: Get the latest Stock Analysis on CTIC - FREE

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Salesforce.com (CRM) - FREE Research Report

Webb Maynard G Jr, who is Director at Salesforce.com, sold 30,000 shares at $69.16 on Oct. 1, 2015. Following this transaction, the Director owned 43,941 shares meaning that the stake was reduced by 40.57% with the 30,000-share transaction.

The shares most recently traded at $71.73, up $2.57, or 3.59% since the insider transaction. Historical insider transactions for Salesforce.com go as follows:

  • 4-Week # shares sold: 3,209
  • 12-Week # shares sold: 8,356
  • 24-Week # shares sold: 111,758

The average volume for Salesforce.com has been 3.8 million shares per day over the past 30 days. Salesforce.com has a market cap of $45.8 billion and is part of the technology sector and computer software & services industry. Shares are up 22.93% year-to-date as of the close of trading on Thursday.

salesforce.com, inc. provides enterprise cloud computing solutions, with a focus on customer relationship management to various businesses and industries worldwide. Currently, there are 26 analysts who rate Salesforce.com a buy, 1 analyst rates it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CRM - FREE

TheStreet Quant Ratings

rates Salesforce.com as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, compelling growth in net income, good cash flow from operations and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full

Salesforce.com Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Accelerate Diagnostics (AXDX) - FREE Research Report

Ten Brink Frank Jm, who is Director at Accelerate Diagnostics, bought 9,800 shares at $15.24 on Oct. 1, 2015. Following this transaction, the Director owned 9,800 shares meaning that the stake was boosted by 100% with the 9,800-share transaction.

Reichling Steven, who is Cfo at Accelerate Diagnostics, bought 600 shares at $15.23 on Oct. 1, 2015. Following this transaction, the Cfo owned 700 shares meaning that the stake was boosted by 600% with the 600-share transaction.

The shares most recently traded at $16.59, up $1.36, or 8.2% since the insider transaction. Historical insider transactions for Accelerate Diagnostics go as follows:

  • 4-Week # shares bought: 500
  • 12-Week # shares bought: 500
  • 24-Week # shares bought: 500

The average volume for Accelerate Diagnostics has been 186,700 shares per day over the past 30 days. Accelerate Diagnostics has a market cap of $723.6 million and is part of the health care sector and health services industry. Shares are down 9.8% year-to-date as of the close of trading on Thursday.

Accelerate Diagnostics, Inc., an in vitro diagnostics company, focuses on developing and commercializing solutions for the diagnosis of serious infections. The company is developing ID/AST System, a rapid diagnostic platform for the diagnosis of infectious pathogens.

Exclusive Offer: Get the latest Stock Analysis on AXDX - FREE

TheStreet Quant Ratings

rates Accelerate Diagnostics as a

sell

. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity and weak operating cash flow. Get the full

Accelerate Diagnostics Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.